M. V. D. van de Sande

Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.

D. D. Giuseppe, B. Gudbjornsson, F. Iannone, 2024, Seminars in Arthritis & Rheumatism.

Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network

B. Gudbjornsson, F. Iannone, B. Glintborg, 2023, RMD Open.

EULAR study group on ‘MHC-I-opathy’: identifying disease-overarching mechanisms across disciplines and borders

J. Bowes, N. de Vries, M. Breban, 2023, Annals of the Rheumatic Diseases.